erythropoietin

(redirected from Erythropoetin)
Also found in: Dictionary, Thesaurus, Encyclopedia.

erythropoietin

 [ĕ-rith″ro-poi´ĕ-tin]
a glycoprotein hormone secreted by the kidney in the adult and by the liver in the fetus, which acts on stem cells of the bone marrow to stimulate red blood cell production (erythropoiesis).
recombinant human erythropoietin epoetin.

e·ryth·ro·poi·e·tin (EPO),

(ĕ-rith'rō-poy'ĕ-tin), [MIM*133170]
A protein containing sialic acid that enhances erythropoiesis by stimulating formation of proerythroblasts and release of reticulocytes from bone marrow; it is formed by the kidney and liver, and possibly by other tissues, and can be detected in human plasma and urine.

erythropoietin

/eryth·ro·poi·e·tin/ (-poi´ĕ-tin) a glycoprotein hormone secreted by the kidney in the adult and by the liver in the fetus, which acts on stem cells of the bone marrow to stimulate red blood cell production (erythropoiesis).
recombinant human erythropoietin  (r-HuEPO) epoetin.

erythropoietin

(ĭ-rĭth′rō-poi-ē′tĭn)
n.
1. A glycoprotein hormone that stimulates the production of red blood cells by stem cells in bone marrow. Produced mainly by the kidneys, it is released in response to decreased levels of oxygen in body tissue.
2. Epoetin alfa.

erythropoietin (EPO)

[erith′rōpō·ē′tin]
Etymology: Gk, erythros + poiein, to make
a glycoprotein hormone synthesized mainly in the kidneys and released into the bloodstream in response to anoxia. The hormone acts to stimulate and to regulate the production of erythrocytes and thus increases the oxygen-carrying capacity of the blood. See also erythropoiesis.

EPO

A gene on chromosome 7q22 that encodes erythropoietin, a secreted, glycosylated cytokine found in the plasma, which regulates red cell production by promoting erythroid differentiation and initiating haemoglobin synthesis. Erythropoietin plays a neuroprotective role in response to brain injury and is antiapoptotic.

Molecular pathology
Genetic variability of EPO has been linked to microvascular complications of diabetes type 2, including diabetic retinopathy, nephropathy leading to end-stage renal disease, and neuropathy

erythropoietin

EPO Physiology A 46 kD glycoprotein colony-stimulating factor produced predominantly by cells adjacent to the proximal renal tubules in response to signals from an oxygen-sensitive substances in the kidneys–eg, heme Adverse effects Chest pain, swelling, tachycardia, headache, HTN; erythropoietin–EP binds to receptors in erythroid precursors that mature into RBCs; EP is ↑ by hypoxia or by ectopic production from tumors–eg, cerebellar hemangioblastoma, hepatoma, pheochromocytoma, uterine leiomyoma, and renal cell carcinoma; it may not be ↑ in anemic premature infants, and is ↓ in 2º anemia, chronic inflammation, P vera, and certain CAs and may be useful in myeloma-related anemia; EP therapy is indicated for HIV-related anemia, anemia of renal failure and prematurity; it ↑ number of units of autologous RBCs that may be donated before surgery, for ↑ number of units that may be phlebotomized in Pts with hemochromatosis and to ↑ units that may be drawn from a person with a rare blood type

e·ryth·ro·poi·e·tin

(ĕ-rith'rō-poy'ĕ-tin)
A protein that enhances erythropoiesis by stimulating formation of proerythroblasts and releasing reticulocytes from bone marrow; secreted mainly by the kidney and possibly by other tissues.

Erythropoietin

A hormone produced by the kidneys that stimulates the production of red blood cells by bone marrow.
Mentioned in: Dialysis, Kidney

erythropoietin

kidney-derived protein promoting erythrocyte formation within bone marrow

erythropoietin

a glycoprotein hormone secreted mainly by the kidney. A profactor, erythropoietinogen, is first produced in the liver, transferred to the kidney and converted to active erythropoietin in the kidney. The erythropoietin acts on stem cells of the bone marrow to stimulate red blood cell production (erythropoiesis). Called also erythropoietin stimulating factor, erythrogenin.

recombinant erythropoietin
used to treat dogs and cats with nonregenerative anemia of renal disease; animals develop antibodies to the human product.
erythropoietin stimulating factor
see erythropoietin (above).
References in periodicals archive ?
Green Cross filed for regulatory approval with the KFDA for recombinant Factor VIII in the second quarter of 2008 and Green Cross has completed Phase III studies for erythropoetin.
Some of Locus Discovery's drug design programs include small molecule mimetics of erythropoetin, anti-viral compounds based on a novel target called GP41, and other programs in cancer, infectious diseases, asthma, and neurological and other disorders.
and Canada: erythropoetin, pegylated G-CSF (granulocyte-colony stimulating factor), Interferon-Alpha, recombinant Factor VIII, and Enbrel([R]) (etanercept).
Some of Locus Discovery's drug discovery programs include small molecule mimetics of erythropoetin, anti-viral compounds based on a novel target called GP41, and other programs in cancer, infectious diseases, and neurological and other disorders.
Green Cross plans to file for regulatory approval with the Korean FDA for recombinant Factor VIII in the first quarter of 2008, and Green Cross has completed Phase III studies for erythropoetin.
The authors found that treatment of these patients with Erythropoetin significantly improved the symptoms of these patients.
Some of the more advanced drug discovery programs include small molecule mimetics of erythropoetin, and broad-spectrum anti-viral compounds based on a novel anti-viral target called GP41.
Roche is offering free antibody testing to physicians for those patients in whom there are concerns that anti-erythropoetin antibodies may have already developed with other erythropoetin therapy.
Some of the more advanced drug discovery programs include a small molecule mimetic of erythropoetin, and a broad spectrum anti-viral compound based on a novel anti-viral target called GP41.
Dragon Pharmaceuticals (the "Company) is pleased to announce a number of significant developments in its international marketing of Erythropoetin ("EPO") since its last international marketing update on October 6, 2000.
Small molecule erythropoetin mimetic -- One of the most successful and largest selling biotechnology products in the world is erythropoetin, sold by Amgen as Epogen(R) and Johnson & Johnson as Procrit(R).